FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100941262> ?p ?o ?g. }

• W2100941262 endingPage "2643" @default.
• W2100941262 startingPage "2637" @default.
• W2100941262 abstract "Abstract BACKGROUND Vincristine (VCR) is widely used to treat patients with malignant disease; among the patients treated with VCR are children with brain tumors. In vitro studies have demonstrated that the cytotoxic activity of VCR is related to both extracellular concentration and duration of exposure. The attainment of higher plasma concentrations by injecting larger bolus doses of VCR has been limited by concerns about neurotoxicity. One possible alternative strategy for enhancing the antitumor efficacy of VCR involves prolonging the duration of in vivo exposure. Therefore, the authors explored the neurotoxicity and pharmacokinetics of VCR administered via a 96‐hour continuous infusion after administration of a conventional bolus dose in a pediatric population. METHODS The current study included 16 patients, 11 of whom were males. The median age of the study population was 4.8 years (range, 1.7–15.8 years). The diagnoses included intrinsic pontine glioma ( n = 4), ependymoma ( n = 5), astrocytoma ( n = 3), medulloblastoma/primitive neuroectodermal tumor (PNET; n = 2), ganglioglioma ( n = 1), and choroid plexus carcinoma ( n = 1). Of the 16 patients, 5 were newly diagnosed, and the remaining 11 had disease recurrences, 8 of which arose after radiotherapy. Treatment included cyclophosphamide 65 mg/kg administered intravenously over 1 hour on Day 1, a bolus of VCR 1.5 mg/m 2 administered intravenously on Day 2, and VCR 0.5 mg/m 2 per 24 hours administered via continuous intravenous infusion on Days 2–5. Thus, a total VCR dose of 3.5 mg/m 2 was administered via infusion over 4 days. Fifteen patients received 2 courses of treatment at 21–28‐day intervals, and a total of 31 treatment courses were administered. VCR concentrations in plasma samples were measured using high‐performance liquid chromatography. RESULTS Jaw pain, constipation, mild abdominal pain, and depressed reflexes were common. However, only 1 of 31 courses was associated with Grade III toxicity, and no Grade IV toxicity (e.g., cranial nerve palsy, ileus, inappropriate antidiuretic hormone secretion, seizures, hallucinations, etc.) was noted. The steady‐state plasma concentration of VCR during continuous infusion ranged from 1 to 3 μg/L in all patients. Responses after 2 courses were evaluated in 14 of 16 patients. A complete response was noted in one patient (astrocytoma), a partial response in three patients (one each with astrocytoma, ependymoma, and PNET), stable disease in seven patients, and disease progression in three patients. CONCLUSIONS Continuous infusion of VCR after a conventional bolus dose plus cyclophosphamide for children with tumors of the central nervous system did not result in significant neurotoxicity and appeared to be a safe strategy for achieving increased systemic exposure. Cancer 2004. © 2004 American Cancer Society." @default.
• W2100941262 created "2016-06-24" @default.
• W2100941262 creator A5005404102 @default.
• W2100941262 creator A5026589285 @default.
• W2100941262 creator A5030283472 @default.
• W2100941262 creator A5037141124 @default.
• W2100941262 creator A5086412405 @default.
• W2100941262 creator A5087006095 @default.
• W2100941262 creator A5089527588 @default.
• W2100941262 date "2004-06-02" @default.
• W2100941262 modified "2023-10-12" @default.
• W2100941262 title "Increasing the dosage of vincristine" @default.
• W2100941262 cites W1496892879 @default.
• W2100941262 cites W1941890260 @default.
• W2100941262 cites W1970562637 @default.
• W2100941262 cites W1972264308 @default.
• W2100941262 cites W1973694210 @default.
• W2100941262 cites W1974721564 @default.
• W2100941262 cites W1984844858 @default.
• W2100941262 cites W1988924915 @default.
• W2100941262 cites W1994226708 @default.
• W2100941262 cites W2010415785 @default.
• W2100941262 cites W2015131798 @default.
• W2100941262 cites W2021045134 @default.
• W2100941262 cites W2021679590 @default.
• W2100941262 cites W2029424774 @default.
• W2100941262 cites W2036695863 @default.
• W2100941262 cites W2039782626 @default.
• W2100941262 cites W2049454435 @default.
• W2100941262 cites W2057631355 @default.
• W2100941262 cites W2077670234 @default.
• W2100941262 cites W2078200326 @default.
• W2100941262 cites W2083616014 @default.
• W2100941262 cites W2090815264 @default.
• W2100941262 cites W2094129598 @default.
• W2100941262 cites W2121896285 @default.
• W2100941262 cites W2141151491 @default.
• W2100941262 cites W2145201636 @default.
• W2100941262 cites W2160280166 @default.
• W2100941262 cites W2170446694 @default.
• W2100941262 cites W2338983050 @default.
• W2100941262 cites W4211071303 @default.
• W2100941262 cites W4233238196 @default.
• W2100941262 doi "https://doi.org/10.1002/cncr.20220" @default.
• W2100941262 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15197807" @default.
• W2100941262 hasPublicationYear "2004" @default.
• W2100941262 type Work @default.
• W2100941262 sameAs 2100941262 @default.
• W2100941262 citedByCount "35" @default.
• W2100941262 countsByYear W21009412622013 @default.
• W2100941262 countsByYear W21009412622014 @default.
• W2100941262 countsByYear W21009412622015 @default.
• W2100941262 countsByYear W21009412622017 @default.
• W2100941262 countsByYear W21009412622020 @default.
• W2100941262 countsByYear W21009412622021 @default.
• W2100941262 countsByYear W21009412622022 @default.
• W2100941262 countsByYear W21009412622023 @default.
• W2100941262 crossrefType "journal-article" @default.
• W2100941262 hasAuthorship W2100941262A5005404102 @default.
• W2100941262 hasAuthorship W2100941262A5026589285 @default.
• W2100941262 hasAuthorship W2100941262A5030283472 @default.
• W2100941262 hasAuthorship W2100941262A5037141124 @default.
• W2100941262 hasAuthorship W2100941262A5086412405 @default.
• W2100941262 hasAuthorship W2100941262A5087006095 @default.
• W2100941262 hasAuthorship W2100941262A5089527588 @default.
• W2100941262 hasBestOaLocation W21009412621 @default.
• W2100941262 hasConcept C112705442 @default.
• W2100941262 hasConcept C118552586 @default.
• W2100941262 hasConcept C126322002 @default.
• W2100941262 hasConcept C141071460 @default.
• W2100941262 hasConcept C142724271 @default.
• W2100941262 hasConcept C2776694085 @default.
• W2100941262 hasConcept C2776755627 @default.
• W2100941262 hasConcept C2778186239 @default.
• W2100941262 hasConcept C2778227246 @default.
• W2100941262 hasConcept C2779429289 @default.
• W2100941262 hasConcept C2779491297 @default.
• W2100941262 hasConcept C2779904719 @default.
• W2100941262 hasConcept C2780789225 @default.
• W2100941262 hasConcept C2781432949 @default.
• W2100941262 hasConcept C2908647359 @default.
• W2100941262 hasConcept C29730261 @default.
• W2100941262 hasConcept C42219234 @default.
• W2100941262 hasConcept C43376680 @default.
• W2100941262 hasConcept C502942594 @default.
• W2100941262 hasConcept C71924100 @default.
• W2100941262 hasConcept C99454951 @default.
• W2100941262 hasConceptScore W2100941262C112705442 @default.
• W2100941262 hasConceptScore W2100941262C118552586 @default.
• W2100941262 hasConceptScore W2100941262C126322002 @default.
• W2100941262 hasConceptScore W2100941262C141071460 @default.
• W2100941262 hasConceptScore W2100941262C142724271 @default.
• W2100941262 hasConceptScore W2100941262C2776694085 @default.
• W2100941262 hasConceptScore W2100941262C2776755627 @default.
• W2100941262 hasConceptScore W2100941262C2778186239 @default.
• W2100941262 hasConceptScore W2100941262C2778227246 @default.
• W2100941262 hasConceptScore W2100941262C2779429289 @default.
• W2100941262 hasConceptScore W2100941262C2779491297 @default.

• next